PDCD1 and vitiligo: The positive association between cutaneous adverse events (particularly vitiligo) and favorable therapeutic outcomes in melanoma has been shown with various agents including biochemotherapy (44, 45), interferon (46), ipilimumab (47), and anti-PD-1 ICI (48, 49).